title: Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement.
abstract: We compared the concentrations of dopaminergic substances in the plasma and cerebrospinal fluid (CSF) with clinical severity in patients with Parkinson's disease (PD) under L-dopa/carbidopa treatment and under L-dopa/carbidopa+tolcapone treatment. Compared with treatment with L-dopa/carbidopa alone, the co-administration of tolcapone produced a significant decrease in clinical severity; a remarkable reduction in the 3-O-methyldopa (3-OMD) concentration and significant increase in the L-dopa concentration both in the plasma and CSF; and a significant increase in the dopamine concentration in the CSF. The clinical effects of tolcapone were closely correlated with the reduction in the 3-OMD concentration, but not with the increase in the dopamine and L-dopa concentrations in the CSF.
authors.affiliation: Department of Neurology, Iwate Medical University, Morioka, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Tohgi
authors.forename: T
authors.initials: T
authors.lastname: Abe
authors.forename: K
authors.initials: K
authors.lastname: Yamazaki
authors.forename: M
authors.initials: M
authors.lastname: Saheki
authors.forename: S
authors.initials: S
authors.lastname: Takahashi
authors.forename: Y
authors.initials: Y
authors.lastname: Tsukamoto
mesh_terms: D015102:3,4-Dihydroxyphenylacetic Acid / Q000097:blood / Q000134:cerebrospinal fluid; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001577:Benzophenones / Q000494:pharmacology*; D002230:Carbidopa / Q000494:pharmacology; D065098:Catechol O-Methyltransferase Inhibitors; D004298:Dopamine / Q000097:blood / Q000134:cerebrospinal fluid / Q000502:physiology*; D006719:Homovanillic Acid / Q000097:blood / Q000134:cerebrospinal fluid; D006801:Humans; D007980:Levodopa / Q000097:blood / Q000134:cerebrospinal fluid / Q000494:pharmacology; D008875:Middle Aged; D009596:Nitrophenols; D010300:Parkinson Disease / Q000188:drug therapy*; D000077867:Tolcapone; D014443:Tyrosine / Q000031:analogs & derivatives / Q000097:blood / Q000134:cerebrospinal fluid
chemical_list: D000978:Antiparkinson Agents; D001577:Benzophenones; D065098:Catechol O-Methyltransferase Inhibitors; D009596:Nitrophenols; D015102:3,4-Dihydroxyphenylacetic Acid; D014443:Tyrosine; D007980:Levodopa; D000077867:Tolcapone; D002230:Carbidopa; C008404:3-methoxytyrosine; D004298:Dopamine; D006719:Homovanillic Acid